LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Aandelen Lijst・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

27.33 -0.51

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

26.44

Max

27.48

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.6M -108M
Verkoop	7.1M 20M
K/W Sectorgemiddelde	3.836 66.845
EPS	-1.85
Winstmarge	-541.088
Werknemers	539
EBITDA	-18M -120M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+43.46% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	140M 1.7B
Vorige openingsprijs	27.84
Vorige sluitingsprijs	27.33

Nieuwssentiment

By Acuity

50%

154 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

28.04 / 30.06 Steun & Weerstand

Agios Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 nov 2025, 15:05 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Nvidia, Lowe's, Target, Semrush, MP Materials, Plug Power, Dycom, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Agios Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

43.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 39.71 USD 43.46%

Hoogste 65 USD

Laagste 25 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Agios Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Agios Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

28.04 / 30.06Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

The bullish and bearish events are balanced.

Sentiment

By Acuity

154 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.